
    
      This is a global, Phase 3, randomized study of zanubrutinib versus ibrutinib in approximately
      600 participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic
      lymphoma.

      The primary efficacy endpoint is overall response rate determined by investigator assessment.
      Participants will be randomized in a 1:1 manner to either zanubrutinib or ibrutinib.
      Treatment with zanubrutinib and ibrutinib will be open label.
    
  